combination drug-Mansoura University-peripheral artery disease

The term **combination drug-Mansoura University-peripheral artery disease** refers to the antithrombotic combination regimens evaluated in a clinical trial (NCT04042103) sponsored by Mansoura University for patients with symptomatic peripheral artery disease (PAD) undergoing lower limb revascularization. The study compares two distinct combination therapies: **Clopidogrel Aspirin Therapy (CAT)**, which combines the P2Y12 inhibitor clopidogrel (75 mg) with low-dose aspirin (81 mg), and **Apixaban Aspirin Therapy (AAT)**, which combines the direct factor Xa inhibitor apixaban (2.5 mg twice daily) with low-dose aspirin (81 mg). These therapies are designed to reduce the risk of major adverse limb events (MALE) and major adverse cardiovascular events (MACE) by providing dual inhibition of platelet activation and, in the case of AAT, the coagulation cascade. The trial aims to determine the optimal antithrombotic strategy for maintaining vessel patency and preventing ischemic complications following surgical or endovascular revascularization.

Brand names

PlavixEliquis

Other names

CATAATClopidogrel Aspirin TherapyApixaban Aspirin Therapy